PUBLISHER: The Business Research Company | PRODUCT CODE: 1760674
PUBLISHER: The Business Research Company | PRODUCT CODE: 1760674
Pernicious anemia diagnosis and treatment refers to the process of identifying and managing a condition where the body is unable to produce sufficient healthy red blood cells due to impaired absorption of vitamin B12, often due to a lack of intrinsic factor. The diagnosis involves evaluating clinical symptoms such as fatigue, weakness, and neurological issues. Treatment aims to restore vitamin B12 levels, promote normal red blood cell production, alleviate symptoms, and prevent long-term health complications.
The primary types of pernicious anemia diagnosis and treatment include complete blood count (CBC) tests, vitamin B12 deficiency tests, and intrinsic factor deficiency tests. A CBC test is a common blood test that measures various blood components, helping to identify abnormal levels of red blood cells and hemoglobin, which can indicate anemia and assist in diagnosing the condition. Treatments vary and include vitamin B12 injections, oral vitamin B12 pills, and intranasal sprays, all of which are administered via different routes such as injection, oral, and intranasal. These treatments are utilized by end users, including hospitals, clinics, diagnostic centers, and other healthcare settings.
The pernicious anemia diagnosis and treatment market research report is one of a series of new reports from The Business Research Company that provides pernicious anemia diagnosis and treatment market statistics, including the pernicious anemia diagnosis and treatment industry's global market size, regional shares, competitors with an pernicious anemia diagnosis and treatment market share, detailed pernicious anemia diagnosis and treatment market segments, market trends and opportunities, and any further data you may need to thrive in the pernicious anemia diagnosis and treatment industry. This pernicious anemia diagnosis and treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The pernicious anemia diagnosis and treatment market size has grown strongly in recent years. It will grow from $1.42 billion in 2024 to $1.52 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth during the historic period can be attributed to rising awareness of vitamin B12 deficiency, the increasing prevalence of autoimmune disorders, the growing geriatric population, enhanced physician education on anemia, and the availability of both oral and injectable vitamin B12 treatments.
The pernicious anemia diagnosis and treatment market size is expected to see strong growth in the next few years. It will grow to $1.97 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth during the forecast period can be attributed to the expansion of telemedicine services, increasing demand for early diagnosis, a growing focus on personalized medicine, government screening initiatives, and a rising patient preference for non-invasive treatments. Key trends in the forecast period include the development of long-acting vitamin B12 formulations, a growing use of home-based diagnostic kits, the integration of artificial intelligence (AI) in anemia detection, the rise of digital health monitoring tools, and advancements in diagnostic technologies.
The increasing prevalence of vitamin B12 deficiency is expected to fuel growth in the pernicious anemia diagnosis and treatment market in the coming years. Vitamin B12 deficiency occurs when the body lacks sufficient amounts of the vitamin to produce enough red blood cells, leading to symptoms such as fatigue, weakness, and neurological issues. The prevalence of vitamin B12 deficiency is rising due to the growing adoption of plant-based diets, which often lack adequate natural sources of B12 and may result in insufficient intake without proper supplementation. This deficiency supports the need for pernicious anemia diagnosis and treatment, as low B12 levels directly hinder red blood cell production, prompting doctors to administer B12 supplementation as a primary and effective treatment approach. For example, in February 2023, a report by the National Health Service (NHS) indicated that both vitamin B12 and folate deficiencies are more common among older adults, affecting approximately 1 in 10 individuals aged 75 or older and 1 in 20 of those aged 65 to 74. Therefore, the rising prevalence of vitamin B12 deficiency is contributing to the growth of the pernicious anemia diagnosis and treatment market.
Leading companies in the pernicious anemia diagnosis and treatment market are focusing on developing innovative solutions, such as vitamin B12 maintenance therapy, to improve patient adherence and long-term disease management. Vitamin B12 maintenance therapy involves regular, ongoing supplementation through oral tablets, injections, or nasal sprays to maintain adequate B12 levels and prevent the recurrence of deficiency-related symptoms. For example, in February 2024, Lupin Pharmaceuticals Inc., a pharmaceutical company based in India, launched a cyanocobalamin nasal spray (500 mcg/spray) as a non-invasive alternative for vitamin B12 supplementation. This nasal spray offers a convenient and effective option for patients with pernicious anemia who face challenges with oral vitamin B12 forms. It enhances B12 absorption and supports the management of vitamin B12 deficiency, ultimately improving patient compliance and treatment outcomes.
In February 2025, Lightstone Group, a U.S.-based investment firm, acquired Pfizer's Durham facility for $41.1 million. This acquisition enabled the firm to add a move-in-ready, state-of-the-art clinical supply cGMP facility, built to meet the highest quality standards, to its growing portfolio. Pfizer Inc., a U.S.-based manufacturer, produces vitamin B12 capsules for pernicious anemia treatment.
Major players in the pernicious anemia diagnosis and treatment market are Pfizer Inc., F.Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb Company, Thermo Fisher Scientific Inc., GSK plc, Takeda Pharmaceutical Company Limited, Lupin Limited, Eli Lilly and Company, Amgen Inc., DSM Nutritional Products AG, Bio-Rad Laboratories Inc., CSL Vifor Pharma, Daiichi Sankyo Co. Ltd., Par Pharmaceutical Companies Inc., AdvaCare Pharma, and Monobind Inc.
North America was the largest region in the pernicious anemia diagnosis and treatment market in 2024. The regions covered in pernicious anemia diagnosis and treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the pernicious anemia diagnosis and treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The pernicious anemia diagnosis and treatment market consists of revenues earned by entities by providing services such as antibody testing, neurological evaluation services, nutritional counseling, and telemedicine consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The pernicious anemia diagnosis and treatment market also includes sales of methylcobalamin supplements, combination supplements, and anemia management trackers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Pernicious Anemia Diagnosis And Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on pernicious anemia diagnosis and treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for pernicious anemia diagnosis and treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pernicious anemia diagnosis and treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.